Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PFE
Strong BuyFull HouseAPPROVEPfizer Inc. · Healthcare · United States · $159.4B · Avg Vol: $1.0B/d
This is the US line of Pfizer, which pays a high, well-covered dividend funded by a large marketed portfolio and has been cutting costs and deleveraging after its pandemic-era acquisitions, screening cheap on value (V76). Nothing adverse is known on accounting or solvency beyond disclosed litigation and government pricing matters.
COMPANY DESCRIPTION
Pfizer Inc. is a global pharmaceutical giant engaged in the research, development, manufacture, and sale of innovative medicines and vaccines across a wide array of therapeutic areas. The company's competitive moat stems from its robust R&D pipeline, extensive portfolio of blockbuster drugs, and formidable intellectual property protection, enabling it to deliver life-changing treatments worldwide. As a market leader, Pfizer leverages its global scale and distribution network to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 101.2B | 59.6B | 63.6B | 62.6B | -14.8% | 63.7B | 62.2B | 59.8B | -2.2% |
| EPS | 5.59 | 0.38 | 1.42 | 1.37 | -37.4% | 0.76 | 1.27 | 1.23 | -5.2% |
| Shares | 5.6B | 5.6B | 5.7B | 5.7B | +1.2% | 5.7B | — | — | — |
| Debt | 34.9B | 70.8B | 63.6B | 64.0B | 22.4% | 63.5B | — | — | — |
| Equity | 95.7B | 89.0B | 88.2B | 86.5B | -3.3% | — | — | — | — |
| Op CF | 29.3B | 8.7B | 12.7B | 11.7B | -26.3% | 13.4B | — | — | — |
| Inv CF | -15.8B | -32.3B | 2.7B | -1.4B | — | — | — | — | — |
| Fin CF | -14.8B | 26.1B | -17.1B | -10.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PFE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PFE | Pfizer Inc.(you) | $159.4B | 88 | Strong Buy |
| NVO | Novo Nordisk A/S | $201.6B | 89 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| GSK.L | GSK plc | $100.5B | 86 | Strong Buy |
| SAN.PA | Sanofi | $107.2B | 93 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 98 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 74 | Buy |
| ROP.SW | Roche Holding AG | $353.1B | 88 | Strong Buy |
| NOVN.SW | Novartis AG | $290.6B | 81 | Strong Buy |
| ABBV | AbbVie Inc. | $451.5B | 86 | Strong Buy |
Peer medians: ROE 2.8% · P/E 24.3x · Gross margin 52.6%